OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical and Experimental Allergy is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID‐19 vaccine	184
Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID‐19	118
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases	89
The use of biologics in food allergy	60
Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients	59
The epidemiology of eczema in children and adults in England: A population‐based study using primary care data	54
Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double‐blind placebo‐controlled trial	54
Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis	54
Mechanisms of oral immunotherapy	48
Paediatric and adolescent asthma: A narrative review of telemedicine and emerging technologies for the post‐COVID‐19 era	43
Digital health interventions in children with asthma	42
Skincare interventions in infants for preventing eczema and food allergy: A cochrane systematic review and individual participant data meta‐analysis	41
BSACI 2021 guideline for the management of egg allergy	40
Treating severe asthma: Targeting the IL‐5 pathway	37
BSACIguideline for the set‐up of penicillin allergy de‐labelling services by non‐allergists working in a hospital setting	36
Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate‐to‐severe asthma	36
Frequency of guideline‐defined cow's milk allergy symptoms in infants: Secondary analysis of EAT trial data	34
Treatment effectiveness for Vocal Cord Dysfunction in adults and adolescents: A systematic review	33
Adverse reactions to COVID‐19 vaccines: A practical approach	33
Trends in eczema prevalence in children and adolescents: A Global Asthma Network Phase I Study	32
Mast cell activation tests by flow cytometry: A new diagnostic asset?	31
Clinical evaluation of type 2 disease status in a real‐world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil counts	29
The Polysorbate containing AstraZeneca COVID‐19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients	28
BSACIguideline for the diagnosis and management of pollen food syndrome in theUK	28
Revisiting Asian chronic rhinosinusitis in the era of type 2 biologics	28

Switching between biologics in severe asthma patients. When the first choice is not proven to be the best